Benchmark Reiterates Speculative Buy on Reviva Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson reiterates a Speculative Buy rating on Reviva Pharmaceuticals (NASDAQ:RVPH) and maintains a $17 price target.

April 16, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst reiterates Speculative Buy rating on Reviva Pharmaceuticals with a $17 price target.
The reiteration of a Speculative Buy rating and a $17 price target by a Benchmark analyst suggests a positive outlook on Reviva Pharmaceuticals' stock. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100